Dockets Management Branch
The Food and Drug Administration
Department of Health & Human Services, Rm. 1-23
12420 Parklawn Dr.
Rockville, MD 20857

Date: July 27, 1999

Re: 99P-1340/CP 1 — Petition to Have Eternity eau de parfum declared "Misbranded" - 133

Dear Sir or Madam:

In May 1999, the Environmental Health Network (EHN) submitted the above petition to have Calvin Klein's *Eternity* eau de parfum declared "misbranded." I am writing because I fully support this petition and request that the FDA give it careful attention with regard to your regulations 21CFR Sec. 740.1, 21CFR Sec. 740.2, and 21CFR Sec. 740.10. Regulation 21CFR Sec. 740.10 states:

- Each ingredient used in a cosmetic product and each finished cosmetic product shall be adequately substantiated for safety prior to marketing. Any such ingredient or product whose safety is not adequately substantiated prior to marketing is misbranded unless it contains the following conspicuous statement on the principal display panel:
- "Warning The safety of this product has not been determined."

As the petition shows, *Eternity* contains toxic ingredients and ingredients whose safety have not been substantiated. There is no warning label on its packaging.

We all have a right to know the status of safety testing of the ingredients in products such as *Eternity* so that we can protect ourselves and our families from toxic chemicals that may cause health problems. Most people are not aware that most fragrance materials have only limited safety testing. They wrongfully assume these products are safe to use in any setting and are surprised when people complain.

Like tobacco smoke, the harmful chemicals currently used in these products may affect the health of many people, including: people with asthma, chemical sensitivities, chronic fatigue, and other environmental illnesses. Children are particularly vulnerable to toxic chemicals found in products purchased and used by their parents, caregivers and teachers. When I am exposed to fragrance products I can experience any of the following symptoms based upon the chemical fragrance product I encounter:

o	asthma	🕱 double vision	incoherence	🕱 nausea
	anaphylaxis	ar pain	incontinence	🕱 nose bleeds
	* *	☐ eczema	🕱 irritabílity	🗇 rashes
	breathing difficulty	eyes, watery or dry	☐ joint aches	seizures
	bronchitis	⊠ fatigue	😾 laryngitis	short-term mem. loss
		A flushing	☐ lethargy	🕱 sinusitis
Ø	can't concentrate coughing	M headaches	lymph nodes swell	sneezing
X	depression	heart beat irregularity	mood swings	sores, skin/mouth
•	disorientation	☐ hives	muscle pain/weakness	ss x swallowing difficulty
. /	dizziness	☐ hypertension	nasal congestion	tinnitus
0	other:			
			26 1 1 1 1 111 111	1 ::

Please act on behalf of the millions of people who have suffered physical illness and injury resulting from fragrance exposure at work, at school and in social settings. These toxic chemicals act as powerful barriers to people disabled by asthma and chemical sensitivities. Toxic chemicals in fragrances have already ruined countless lives. Thank you.

Sincerely,	in		
8432 Via Jonima #56	of with Pa	921137	
address; city/st/zip	, Da Jacia, 19	/300/	O 233
99P-134C			C 2-5-5

Newsletters and everyone who feels people have a right to know, please copy, share, tell your friends and WRITE the FDA... today!

first, fold down

Jacquelyn Y. Christian 8432 Via Sonoma #56 La Jolla CA 92037



Attn: 99P-1340/CP 1

Dockets Management Branch
The Food and Drug Administration
Department of Health & Human Services, Rm. 1-23
12420 Parklawn Dr.
Rockville, MD 20857

second, fold up